And it depends on you how soon it will be developed
Pharm Exec's latest annual listing of the top biopharma players paints a stable picture of performance for the usual placeholders, but change and disruption to current business models could upend positioning in the years ahead.
Milestone on Bayer’s path to completing the planned acquisition of Monsanto
DNA evolved to store genetic information, but in principle this special, chain-like molecule can also be adapted to make new materials. Chemists at The Scripps Research Institute (TSRI) have now published an important demonstration of this repurposing of DNA to create new substances with possible medical applications.
“How many different cell types are there in the human body? And how do these differences develop? Nobody really knows,” says Professor Stein Aerts from KU Leuven/VIB. But thanks to a new method developed by his team, that may be about to change.